Factbox-Court challenges to Medicare drug price negotiation plan

(Reuters) – Manufacturers of the 10 prescription drugs subject to price negotiations for the U.S. Medicare program have signed on to participate in the talks by the Oct. 1 deadline even as Novo Nordisk filed a lawsuit to halt the process.At least nine lawsuits were filed between June and late September seeking to block the price negotiation, arguing that the law and forced price cuts would violate various amendments to the U.S. constitution.

The following are key details of the lawsuits:

Company Date Location Drugs named in

filed lawsuit as

likely to be

affected by IRA

Merck & Co June 6 U.S. District Court Diabetes drugs

for the District of Januvia and

Columbia Janumet, cancer

treatment

Keytruda

The U.S. June 9 U.S. District Court NA

Chamber of for the Southern

Commerce District Of Ohio

Western Division

Bristol Myers June 16 U.S. District Court Blood thinner

Squibb for the District of Eliquis, cancer

New Jersey therapy Opdivo

Johnson & July 18 U.S. District Court Blood thinner

Johnson for the District of Xarelto

New Jersey

Pharmaceutica June 21 U.S. District Court NA

l Research For the Western

and District Of Texas

Manufacturers Austin Division

of America

Boehringer Aug 18 U.S. District Court Diabetes drug

Ingelheim for the District Of Jardiance

Connecticut

AstraZeneca Aug 25 U.S. District Court Cancer drug

For the District Of Lynparza, blood

Delaware disorder

treatment

Soliris

Novartis Sept 1 U.S. District Court Heart-failure

for the District of drug Entresto

New Jersey

Novo Nordisk Sept 29 U.S. District Court Insulin Aspart

for the District of for Diabetes

New Jersey

(Reporting by Manas Mishra, Sriparna Roy and Mariam Sunny in Bengaluru; Editing by Bill Berkrot and Sriraj Kalluvila)